Removes the inefficiencies of cancer screening
are often expensive, not very accurate and slow.
could significantly reduce these costs and save lives.
because organisations hold lots of fragmented health records and they can't or won't share them.
would solve the problem, but the quality of records varies greatly depending on where you live.
Unlock your patient Record using the Medici Token
Write your cancer test results to the blockchain
Verify the individual cancer detection machines
Store your results in a secure, patient first way
Learn the big data patterns of the most at risk groups
Get in early as the need for cancer screening increases
Cancer screening will be made available to those most in need
There is a clear use case for the utility tokens enabling you to pay for cancer tests
The earlier we find cancer, the more lives we save. When we "screen" for cancer, we test people who do not have symptoms or signs of cancer. This way, we can find and treat cancers before they become more serious.
The Lancor Blockchain Platform allows patient data to be analysed and stored securely. It lets patients and regional, national and international organisations access the right data at the right time. This will happen in an affordable, safe and timely way.
We're launching the Medici Token to improve access to cancer screening programmes around the world. It is a utility token that allows payment for tests, validates the credentials of the cancer screening devices, and provides secure access to results. For example, when a patient buys Medici Tokens using a simple crypto-wallet app on their phone, they get access to the LBP and information on the screening programmes in their area.
Each Medici Token will be uniquely linked and identifiable to a clinically validated and certified early cancer detection device that has been developed and tested by Tumour Trace, our first partner.
Our technology finds cancer early, fast and cheaply
Imagine being able to detect cancer using the same white light you are reading with now, not dangerous waves like UV or X-rays. Making it possible to achieve real time screening results that are highly accurate, at a cost per test that is affordable across the world.
We imagined this. Then invented it. Then patented it. Then tested it. And is now testing it some more, to show just how powerful the technology is. Find out more in the video.
The ICO Team combines deep knowledge of cancer, government, technology, screening and blockchain with a proven expertise in marketing and commercial delivery.
Building a tested customer centric go-to-market strategy and executing it through focused organisational alignment is in Aamir’s DNA. With 20-years of experience of starting and selling his own businesses, and supporting over 90 other businesses, taking new products to new markets is at the heart of his expertise. Aamir has built scalable business models across several verticals including health, medtech, digital and service industries. Goal-focused and results-oriented, Aamir uses tools and processes so powerfully that beyond execution, he also teaches, consults and coaches.
Roland has over 25 years of Research and Development leadership experience in the pharmaceutical and MedTech industry with a strong focus on risk management and pharmacovigilance. He is an author and co-author of several books and guides for the pharmaceutical industry and healthcare. Roland translates complex scientific discoveries into practical applications to help to understand, diagnose and treat complex cancerous disorders and promotes the cutting-edge technology of early cancer screening by the use of precision and personalized medicine. Roland leads the Academic Research Network (ARN) and is the Medical Director of the International Interdisciplinary Research Center (IIRC) at the Sigmund Freud University in Vienna. He is also a Member of the Interdisciplinary Austrian Blockchain Research Group at Secure Business Austria Research. He studied medicine at the University of Vienna, and in Paris and Moscow, Management at the Vienna University of Economics and Business.
Paul has designed, developed and integrated numerous leading-edge software systems and platforms driven by innovative mathematical and scientific principles for over 25 years. Paul studied for a PhD in Theoretical Physics at King’s College London where he developed and published the Darbyshire operator: a new four-dimensional matrix convolution describing various optical phenomena. After a spell in the City working for a variety of top-tier investment banks as a quantitative analyst in London, New York, Hong Kong and Singapore, Paul returned to scientific research at the University of Oxford developing cutting-edge algorithms for critical decision making in behavioural science. Paul is currently Visiting Professor at the International Interdisciplinary Research Centre, Sigmund Freud University, Vienna.
A Cash Management Specialist with 19 years in-depth experience, Stephen spent 18 years at Barclays’ Corporate Banking Division, moving from Senior Relationship Director into Cash Management Sales and latterly Knowledge Development. Stephen brings his breadth of international insight and acumen in delivering the finest cash management solutions, bringing extensive market and partnership understanding. Stephen is a published author of articles on cash management disciplines and member of ACT Exam Board since 2002.
Gopal has solid business acumen, sound people skills and an astute attention to detail. He is a twice graduate of the University of Cambridge, with an MBA from the Judge Business School and an MEng from the Institute for Manufacturing. As a business development consultant on the Cambridge Accelerate programme, Gopal honed skills in managing multi-market platform business models and developing strategy, and at PwC he fine-tuned his knowledge of finance and EU grant funding.
Robert is a Marketing and digital specialist with more than 20 years experience in cross platform digital transformation, product and proposition development. As a postgraduate marketer he has worked in B2B, B2C, Agency and e-commerce. Robert started his digital and marketing career in Financial Services before working for British Airways and spending time in Latin America. He then moved in to digital consultancy working mainly for blue chip clients. Robert is customer and delivery focused with a common sense approach and the ability to work well with people of all levels.
Prof. Adenike Grange studied Medicine at University of St Andrews and is the author of over 50 scientific papers. She has acted as a consultant to the Federal Ministry of Health, WHO, UNICEF, UNFPA and USAID and was WHO Adviser on the Reproductive Health Programme in Nigeria (1993-1999). She has served as President of the International Paediatric Association recognised as a strong voice in the fight to improve the health of children. In 2007, Adenike Grange was appointed the Minister of Health of the Federal Republic of Nigeria, the first female Minister of Health.
Ryan is a technology design and implementation specialist with 20+ years experience in the financial software industry. Ryan started as a programmer building equity derivative trading systems, progressed through startup companies and consultancy projects, to project management for a number of leading financial software houses. In 2010 Ryan moved in to consultancy working in the risk and regulation area, helping financial companies implement solutions to new regulatory requirements arising from the 2008 financial crisis. He attended UMIST in the early 1990s and closely follows revolutionary computational and scientific innovations
Nick has over 20 years’ experience in taking a wide range of products through all phases of their development from initial concept, through prototyping, testing and in to production within the UK and with manufacturers in the Far East. With a passion for attention to detail in his designs and his particular emphasis on developing unique, creative and innovative engineering solutions to problems, Nick has several patents and design registrations to his name.
Rory is proven and passionate sales leader with over 30 years commercial experience in both the Information Technology and Telecommunications markets. A graduate in Electronic Engineering, he quickly moved into the commercial world where he progressed through roles such as Applications Engineering; Product Management; Business Management; General Management through to his last role as a V.P of Sales and Marketing in a billion dollar USA company, in the Telecommunications sector. He spent the last 23 years building and leading Sales & Marketing teams in Europe & Africa, culminating in his most recent role in directing and leading the entire European and African teams, responsible for c$200m of revenue. He has strong experience in both B2B & B2C environments with most experience in driving Distribution & Reseller acquisition and development strategies & regional Go To Market Models, and more latterly building high-touch large end-user focused sales teams too.
Regional Director, Africa
Having spent half her life in Europe, working in London and Amsterdam Victoria was born and raised in Zimbabwe. She bridges the business and cultural divide and has a deep understanding and respect for the region she serves. A chartered Accountant by trade, Victoria completed the ACCA professional qualification. She has a passion for ethical business, standards and procedure when implementing our vision on the African continent.
Lauren is our newest member of the team joining as Operations Manager. She has five years experience working within finance. Lauren is a very proactive, detailed orientated and organised individual who studied for an Events Management degree at University of Hertfordshire. She also has business management knowledge, organisation and great people skills.
Dr Razvi is a highly qualified surgeon, his eminence in the field of gynaecological cancer diagnostics is complemented by his background in innovation in medicine, having acted as co-inventor for two patents in the field. Khalil has undertaken active research with over 30 peer-reviewed publications and over 50 Conference publications. He also holds many leadership roles in the NHS including Clinical Director for the Obs & Gynae department and Director for Women & Children, the lead Colposcopist in Southend Hospital, and leads the Gynaecological Oncology service for South Essex. Dr Khalil's main responsibility is to offer advice and guidance from outside the company.
Professor Dr. A Min Tjoa has been a full professor and director of the Institute of Software Technology and Interactive Systems at the Vienna University of Technology since 1994. He is the chairperson and board member for committees including, Christian Doppler Foundation for the establishment of high-technology transfer labs in Austria, DEXA Association and is currently the chairman of the Austrian National Competence Center for Security Research. Professor Dr. A Min Tjoa is currently member of the Council of Doctoral Studies in Mathematics, Informatics and Telecommunication which covers all universities in the Toulouse area. He is currently focusing on researching data warehousing, cloud computing, semantic web, security, and non-standard IT-applications.
Julian has worked in equity finance for almost 40 years, in a career that has ranged from Government privatisations at SG Warburg (now UBS), building an Equity department as Head of Sales at SocGen Securities, to specialist mid and small-cap Corporate Broking at WestLB Panmure. He was then a founding partner and Head of Sales of Code (later Nomura Code) Securities, then Head of Life Sciences at Ambrian Partners, and ran Healthcare Specialist Sales at Stifel Nicolas Europe. Having specialised in Healthcare for twenty years, Julian has been directly involved in raising over £3.0bn within the sector through IPOs, M&A, secondary financings and private funding rounds, and has done advisory work for a large range of both quoted and unquoted companies.
With over 25 years of commercial experience in a variety of industries, including retail, pharmaceuticals, commodities trading and insurance, Gary has expertise in Business Intelligence, Data Analytics and Distributed Ledger Technology. He is a Chartered IT Professional (CITP) registered with the British Computer Society (BCS) and holds the ISEB Diploma in Business Analysis. Gary’s expertise in Blockchain, particular in the commercial insurance and legal sectors, sees him listed in the “Top 100 Blockchain influencers” list and has presented at numerous conferences and events since 2015. In 2017 he set up the ICO Meetup London group and runs several Telegram community groups on blockchain, cryptocurrency and ICOs. He advises Blocksure, an Insurance Technology startup, and is technical advisor to Clyde & Co.
James has an in-depth knowledge of several technology sectors; Payment, Security, Big Data, Telecoms, Internet Service Provision and Digital Advertising to name a few. He has formed, built and exited several companies over the last 21 years. His ISP reached no.3 in the UK for registering .uk domain names. James formed a payment gateway which transacted over £300m for his clients. Over 2 million of his apps have been downloaded and he has been interviewed live on the BBC as a technology thought leader. James’s businesses have looked after tens of thousands of clients, including The AA, The NHS and News International. Most recently James has been involved in the Blockchain and crypto-currency space and has been mining Bitcoin and Litecoin since 2013.
Siam is a former RAF Pilot & Currency Trader turned Entrepreneur. Having started up multiple businesses and acquiring dozens of healthy and distressed businesses, he is experienced with business successes and mistakes. After Trading the currency market for 13 years and calling and profiting from several major economic moves such as the 2012 Apple crash, various Bitcoin crashes and the 2015 Black Monday crash, he is perfectly suited for the Crypto market. In 2017 he traded a public Crypto account of $25k to $1m in 4 months and is a well known Crypto Key Note speaker and Advisor.
Our Token pre-sale has now launched giving contributors the chance to shape the future of Cancer screening. Want to be part of it? Sign up to our main sale whitelist here.
We’ve highlighted some of the most frequently asked questions below. Let us know if there are any questions not answered here or within the Whitepaper.
Yes. please go to the Whitepaper download link.
Register your interest and we will send you an email with the relevant investment forms that you will need to complete. You will need to fill out a Know Your Customer (KYC) and Anti-Money Laundering (AML) application. We need to know information about all of our investors and the source of their funds to comply with legal regulations associated with investments of this nature. These checks will become commonplace for all ICOs. We have a compliance team and are careful to make sure that we adhere to all of the necessary investment rules.
1. Register on the Medici website
2. Find the Know Your Customer (KYC) Application link on the main navigation
3. Input necessary personal data (Passport, First Name, Gender, etc.)
KYC Application Process (2 weeks):
– The Medici team will review all KYC submissions by Thursday @12:00PM each week and send confirmation/resubmission emails on Friday. There will be two outcomes:
– Qualified: If your KYC information is correctly submitted you will get a confirmation email and your information will proceed to the AML verification process.
– Resubmit: If you submitted incorrect information, the Medici team will request you to resubmit correct information, a notice will be sent to your email registered on the Medici website with the additional information needed.
Anti-Money Laundering (AML) Verification Process (2 weeks):
– Final Result: the final KYC qualification/disqualification will be announced in bulk after the AML process is concluded in May 2019.
– Qualified: If your KYC+AML submission is QUALIFIED, a KYC qualification email will be sent.
– Disqualified: If your KYC process is DISQUALIFIED, then you will not be eligible to invest in the ICO. A KYC Disqualification Notice will be sent to your email registered on the Medici website by the end of the KYC period.
The minimum investment amount at Crowdsale is US$1,000.
No, but we are incentivising investors to hold on to their Medici Tokens in exchange for bonuses through a Stake Reward scheme.
Stake rewards calculation
10% of Medici Tokens at any ICO are held for stake rewards.
𝑇𝑜𝑡𝑎𝑙 𝑠𝑡𝑎𝑘𝑒 𝑟𝑒𝑤𝑎𝑟𝑑𝑠 𝑎𝑣𝑎𝑖𝑎𝑏𝑙𝑒 = 450,000,000 ∗ 10%
= 4𝟓, 𝟎𝟎𝟎, 𝟎𝟎𝟎
Stake rewards are calculated and awarded from a monthly pool using a 70%
compound interest and 24 month ICO cycle.
Monthly stake reward pool =
45,000,000 ∗ 70%
= 1, 312, 𝟓𝟎𝟎
Your share of these tokens
Your share of the monthly state rewards depends on your own holding, and that of
𝑌𝑜𝑢𝑟 𝑠ℎ𝑎𝑟𝑒 𝑜𝑓 𝑚𝑜𝑛𝑡ℎ𝑙𝑦 𝑠𝑡𝑎𝑘𝑒 𝑟𝑒𝑤𝑎𝑟𝑑𝑠 =
𝑌𝑂𝑈𝑅 𝑡𝑜𝑘𝑒𝑛𝑠 𝑜𝑓 𝑎𝑡 𝑙𝑒𝑎𝑠𝑡 10,000 ℎ𝑒𝑙𝑑 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑟𝑒𝑣𝑖𝑜𝑢𝑠 90 𝑑𝑎𝑦𝑠
𝑇𝑂𝑇𝐴𝐿 𝑡𝑜𝑘𝑒𝑛𝑠 𝑜𝑓 𝑎𝑡 𝑙𝑒𝑎𝑠𝑡 10,000 ℎ𝑒𝑙𝑑 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑟𝑒𝑣𝑖𝑜𝑢𝑠 90 𝑑𝑎𝑦𝑠
You have held 66,667 tokens for more than 3 months
There are 3,000 others who have held an average of 80,000 tokens for over three
Your % share =
3,000 ∗ 80,000
𝑌𝑜𝑢𝑟 𝑎𝑤𝑎𝑟𝑑 𝑡𝑜𝑘𝑒𝑛𝑠 𝑡ℎ𝑎𝑡 𝑚𝑜𝑛𝑡ℎ = 2,187,500 ∗ 0.03%
= 𝟔𝟎𝟕. 𝟔𝟒
With the VC route you take money in stages. You always need to think about raising finance, which can become a distraction. The ICO gives you a chance to have a bigger vision (e.g. making cancer screening available to everyone everywhere) with larger amounts of capital. It creates a chance to work on your bigger vision sooner and gather great momentum.
The initial Medici Tokens distributed will be as follows:
● Total tokens distributed: 450,000,000.
● Unit token price: $0.10.
We will give you a secure wallet address following the KYC and AML processes. You can pay in either Bitcoin, Ethereum, $USD or £GBP
Yes, we will consider ICO pools for a group of people who want to buy in as one transaction is fine (with a minimum investment of $USD10,000)
We decided to go on to the blockchain because of the nature of the data that will be held relating to patient data. The blockchain by nature is verifiable and auditable with all transactions and we believe this will convince the European commission on the GDPR aspect of what we are doing.
On blockchain where all the suppliers of components, manufacturers, the buyer has verifiable, auditable benefits. They know the device is not fake and verifiable by a company called Tumour Trace for example.
The blockchain by nature is verifiable and auditable with all transactions and we believe this will convince the European commission on the GDPR aspect of what we are doing.
Nowhere. We are not looking at that yet. Traditional wisdom is to build tech company and sell in Europe and US. Some med tech companies are underperforming for this very reason. It takes longer and requires deeper pockets. The US takes even longer and you need even deeper pockets.
The price differential between selling in Europe & US is at worst 20%. If you compare India to all of Europe, the market is 5x the size and they are beginning to invest in their value chains. So there is an oportunity for new technologies to make early revenues, prove minimum viable products and get in the value chains as they are being established.
We will work on the US next year when we have the right wisdom and experience to guide us in the right direction.
Yes, we have patents in place covering worldwide jurisdictions.
Many patients have to pay for the screenings themselves. We allow users to use the Medici Token to pay for a test to get done and encourage them to use the token with a 20% discount. In most markets, where people pay themselves, that 20% is material. Here you have the opportunity to buy coins and see value going up or pay for cancer screenings for yourselves and others. A token with genuine need allows a system with a greater number of people wanting to have the token and leads to less fluctuation. The same way that currency works today. I.e. limited £ sterling + people want to buy coffee with it = relatively stable currency.
Because is forms part of their demand. They will be able to incentivise users to participate in the programme.
They can buy blocks of tests at a discount and re-sell them to their patients.
1. As healthy cells become cancerous, there is a tendency for the configurations of the electrons in the cells’ molecules to change. Specifically, the electrons in the outer shells change from being paired to being single.
2. This change causes a change in the magnetic profile of the tissue cells. Healthy tissue, with its paired electrons demonstrates a diamagnetic profile, while malignant tissue, with its unpaired electrons, demonstrates a paramagnetic profile.
3. This means that the magnetic profile of human tissue can be used as a physical (not chemical or biological) biomarker of cancer.
4. These changes can be detected using magnetic force microscopes (MFM) or atomic force microscopes (AFM). However, these machines cost hundreds of thousands of pounds and take up an entire room. OMIS uses the same physical biomarker, but uses light (instead of the magnetic tip of MFM) to detect the magnetic changes in cells.
5. The photoelectric effect, a well established phenomenon of quantum physics, provides that light of the correct range of wavelengths, if shone onto the cells, will create an energy mirror for the valence electrons of those cells. In this case, those wavelengths fall within the visible spectrum, so we can use white light. So, OMIS does not require potentially dangerous ultraviolet, x-ray or microwave radiation to work.
6. Light, as an electromagnetic wave, has two components – an electric field and a magnetic field which sit perpendicular to each other and perpendicular to the direction of travel of the wave. When this white light is shone onto the material, light is reflected from that material. If there is a malignancy growing, there will be changes to the magnetic component of the reflected light. In order to interrogate those changes, we must remove the electric component.
7. When light travels through one medium and reflects off another, there exists an angle of illumination at which the reflected light is plane-polarised, and so the electric field is brought to nil. That angle is known as Brewster’s angle, and in the case of air/water (as it is for use in human tissue) that is 53o. So, we illuminate the sample under two lighting conditions – diffuse light and angled light, and by subtracting one image from the other, we can interrogate the effects of any change in the diamagnetic and paramagnetic responses of the cells under examination. Any change in these responses can be attributed entirely to changes in the outer shells of the molecules of the cells, and thereby the malignant nature of the cells themselves.
8. Such changes create graphical differences that are interpretable by eye, but can be improved on by interpreting through neural networks instead.
9. Applying neural networks, along with quantum noise reduction and other cutting-edge mathematics, the OMIS technology can detect cancer at very high sensitivities and specificities.
No. The Opto-Magnetic Imaging Spectroscopy (OMIS) method requires cells which, if a patient has a cancerous or pre-cancerous growth, may have undergone some change which will cause an altered magnetic field.
So far, we have demonstrated that this works with brush cytology (or “smear” from the cervix), spittle (for oral cancer), plasma (to detect the prostate-specific antigen, “PSA”, in blood for prostate cancer) and biopsy (for colorectal cancer)
The Lancor Scientific team take questions about the upcoming ICO in a discussion session with Siam Kidd.
Chief Medical Officer, Roland Schlesinger and Gopal Rao talk about some of the scientific developments of the Lancor Scientific technology.
Chief Technology Officer, Paul Darbyshire takes questions about the blockchain developments and answers questions on the OMIS tech.
The seed Token Sale is now open to a closed group of participants. The ICO launch marketing has started. We will be completing an extensive programme to raise awareness and anticipation in the build up to the ICO launch.
The Austrian Government has supported Lancor Scientific Ltd. to open a cancer research laboratory in Styria, in partnership with the Technical & Medical Universities of Graz & the Sigmund Freud University Vienna.
The Lancor Token Sale will officially launch to the market. The pre-sale will be available until the ICO Launch date in March unless we reach the hard cap amount before this time.
The Token Sale process will officially open unless we have already reached the hard cap earlier in the sale.
The Alpha version of the Lancor Blockchain Platform will officially go live. We will be able to increase the number of live tests and start working towards a general production release in November 2019.